denkapparat Operations GmbH Invests $390,000 in Halozyme Therapeutics, Inc. $HALO

05 Sep 2026, 04:13 by Teresa Graham · The Cerbat Gem

denkapparat Operations GmbH acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 4,988 shares of the biopharmaceutical company’s stock, valued at approximately $390,000.

A number of other large investors have also added to or reduced their stakes in HALO. Horizon Investment Services LLC purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth $2,254,000. Mizuho Markets Americas LLC increased its position in shares of Halozyme Therapeutics by 270.8% during the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after purchasing an additional 926,526 shares in the last quarter. Chase Investment Counsel Corp purchased a new stake in shares of Halozyme Therapeutics during the second quarter worth approximately $2,035,000. Great Lakes Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $2,821,000. Finally, Aurora Investment Counsel acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at $1,427,000. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 32,478 shares of company stock worth $3,076,604. 2.50% of the stock is currently owned by insiders.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

Positive Sentiment: Analyst maintains Buy rating: HC Wainwright reaffirmed its Buy rating on Halozyme Therapeutics, supporting the bullish view of the company’s growth outlook. HC Wainwright Reaffirms Buy Rating for Halozyme Therapeutics
Positive Sentiment: Higher earnings expectations: Zacks Research raised its FY2026 EPS forecast to $8.24 from $7.56, above the provided consensus estimate of $7.98. It also lifted forecasts for several 2027 and 2028 quarters, including FY2027 EPS to $9.01 from $8.96, indicating improving expectations for Halozyme’s earnings trajectory. Zacks Research Issues Positive Forecast for HALO Earnings
Positive Sentiment: Value and growth appeal: Zacks included HALO among four high-growth stocks with discounted PEG ratios for 2026. The designation may attract investors seeking earnings growth at a relatively reasonable valuation, particularly after Halozyme’s strong recent results and revenue growth. 4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026
Neutral Sentiment: Momentum has been strong: HALO recently hit a new one-year high, reflecting investor enthusiasm and continued upward momentum. However, trading near that high can also increase sensitivity to profit-taking and valuation concerns. Halozyme Therapeutics Hits New 1-Year High
Negative Sentiment: One longer-term estimate was trimmed: Zacks lowered its FY2028 EPS forecast to $10.06 from $10.21, a minor reduction that partially offsets the otherwise positive revisions.

Halozyme Therapeutics Stock Down 0.5%

Shares of NASDAQ:HALO opened at $110.19 on Friday. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The company has a market cap of $12.51 billion, a PE ratio of 32.89, a P/E/G ratio of 0.43 and a beta of 0.88. The stock’s 50-day moving average is $90.76 and its 200 day moving average is $75.82. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $111.15.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the company earned $1.54 earnings per share. Halozyme Therapeutics’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on HALO shares. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday. TD Cowen boosted their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating and issued a $115.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday. Finally, UBS Group reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Get Our Latest Stock Analysis on Halozyme Therapeutics

About Halozyme Therapeutics

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.